This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Quality of Care  • Patient Safety/ Medical Error  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Comment on "Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data"

Steven Woloshin, MD, MS; Lisa M. Schwartz, MD, MS

Arch Intern Med. 2009;169(21):1985-1987.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Here is a challenge: Imagine you are asked to turn a new prescription drug into a blockbuster. The drug is approved by the US Food and Drug Administration (FDA) to treat arthritis pain. That is good news because the arthritis market is huge. But you face some big challenges. First, there are several over-the-counter drugs available that treat pain equally well and at one-fiftieth of the cost. Your only comparative advantage is that your drug causes less gastrointestinal tract (GI) bleeding than other arthritis pain medicines. But this reduction is not very big and only applies to a very small slice (probably <5%) of the market—people at high risk for GI bleeding. And, oh yes, your drug may triple the chance of myocardial infarction.

Do you think you could get physicians to prescribe your drug to over 20 million Americans? Could . . . [Full Text of this Article]

THE VIOXX STORY


MAKING INFORMATION AVAILABLE

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Costs and Consequences of Direct-to-Consumer Advertising for Clopidogrel in Medicaid
Michael R. Law, Stephen B. Soumerai, Alyce S. Adams, and Sumit R. Majumdar
Arch Intern Med. 2009;169(21):1969-1974.
ABSTRACT | FULL TEXT  

Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Joseph S. Ross, David Madigan, Kevin P. Hill, David S. Egilman, Yongfei Wang, and Harlan M. Krumholz
Arch Intern Med. 2009;169(21):1976-1985.
ABSTRACT | FULL TEXT  

Direct-to-Consumer Offers for Free and Discounted Medications on the Internet: A Content Analysis of "e-Samples"
Arch Intern Med. 2009;169(21):2024-2030.
EXTRACT | FULL TEXT